Article Text

other Versions

PDF
Extended report
The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease
  1. Elena Myasoedova1,2,
  2. Arun Chandran1,
  3. Birkan Ilhan3,
  4. Brittny T Major4,
  5. C John Michet1,
  6. Eric L Matteson1,5,
  7. Cynthia S Crowson1,4
  1. 1Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
  2. 2Division of Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  3. 3Department of Internal Medicine, Division of Geriatrics, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey
  4. 4Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
  5. 5Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Cynthia S Crowson, MS, Department of Health Sciences Research, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA; crowson{at}mayo.edu

Abstract

Objective To examine the role of rheumatoid arthritis (RA) flare, remission and RA severity burden in cardiovascular disease (CVD).

Methods In a population-based cohort of patients with RA without CVD (age ≥30 years; 1987 American College of Rheumatology criteria met in 1988–2007), we performed medical record review at each clinical visit to estimate flare/remission status. The previously validated RA medical Records-Based Index of Severity (RARBIS) and Claims-Based Index of RA Severity (CIRAS) were applied. Age- and sex-matched non-RA subjects without CVD comprised the comparison cohort. Cox models were used to assess the association of RA activity/severity with CVD, adjusting for age, sex, calendar year of RA, CVD risk factors and antirheumatic medications.

Results Study included 525 patients with RA and 524 non-RA subjects. There was a significant increase in CVD risk in RA per time spent in each acute flare versus remission (HR 1.07 per 6-week flare, 95% CI 1.01 to 1.15). The CVD risk for patients with RA in remission was similar to the non-RA subjects (HR 0.90, 95% CI 0.51 to 1.59). Increased cumulative moving average of daily RARBIS (HR 1.16, 95% CI 1.03 to 1.30) and CIRAS (HR 1.38, 95% CI 1.12 to 1.70) was associated with CVD. CVD risk was higher in patients with RA who spent more time in medium (HR 1.08, 95% CI 0.98 to 1.20) and high CIRAS tertiles (HR 1.18, 95% CI 1.06 to 1.31) versus lower tertile.

Conclusions Our findings show substantial detrimental role of exposure to RA flare and cumulative burden of RA disease severity in CVD risk in RA, suggesting important cardiovascular benefits associated with tight inflammation control and improved flare management in patients with RA.

  • Rheumatoid Arthritis
  • Disease Activity
  • Cardiovascular Disease

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.